Myllylä VV - Search Results

1

Twelve-month safety of entacapone in patients with Parkinson's disease.

Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group. Myllylä VV, et al. Eur J Neurol. 2001 Jan;8(1):53-60. doi: 10.1046/j.1468-1331.2001.00168.x. Eur J Neurol. 2001. PMID: 11509081 Clinical Trial.

2

Selegiline and blood pressure in patients with Parkinson's disease.

Pursiainen V, Korpelainen TJ, Haapaniemi HT, Sotaniemi AK, Myllylä VV. Pursiainen V, et al. Among authors: myllyla vv. Acta Neurol Scand. 2007 Feb;115(2):104-8. doi: 10.1111/j.1600-0404.2006.00742.x. Acta Neurol Scand. 2007. PMID: 17212613 Clinical Trial.

3

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.

Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Myllylä VV, et al. Eur J Clin Pharmacol. 1993;45(5):419-23. doi: 10.1007/BF00315512. Eur J Clin Pharmacol. 1993. PMID: 8112370 Clinical Trial.

4

Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.

Haapaniemi TH, Kallio MA, Korpelainen JT, Suominen K, Tolonen U, Sotaniemi KA, Myllylä VV. Haapaniemi TH, et al. Among authors: myllyla vv. J Neurol. 2000 Nov;247(11):868-74. doi: 10.1007/s004150070075. J Neurol. 2000. PMID: 11151420 Clinical Trial.

5

Blood pressure and heart rate in parkinsonian patients with and without wearing-off.

Pursiainen V, Korpelainen JT, Haapaniemi TH, Sotaniemi KA, Myllylä VV. Pursiainen V, et al. Among authors: myllyla vv. Eur J Neurol. 2007 Apr;14(4):373-8. doi: 10.1111/j.1468-1331.2007.01672.x. Eur J Neurol. 2007. PMID: 17388983

6

Selegiline as initial treatment in de novo parkinsonian patients.

Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Myllylä VV, et al. Neurology. 1992 Feb;42(2):339-43. doi: 10.1212/wnl.42.2.339. Neurology. 1992. PMID: 1736162 Clinical Trial.

7

Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.

Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllylä VV. Turkka J, et al. Among authors: myllyla vv. Neurology. 1997 Mar;48(3):662-7. doi: 10.1212/wnl.48.3.662. Neurology. 1997. PMID: 9065544 Clinical Trial.

8

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK. Olanow CW, et al. Among authors: myllyla vv. Neurology. 1998 Sep;51(3):825-30. doi: 10.1212/wnl.51.3.825. Neurology. 1998. PMID: 9748034

9

Heart rate variability in patients with untreated Parkinson's disease.

Kallio M, Haapaniemi T, Turkka J, Suominen K, Tolonen U, Sotaniemi K, Heikkilä VP, Myllylä V. Kallio M, et al. Eur J Neurol. 2000 Nov;7(6):667-72. doi: 10.1046/j.1468-1331.2000.00127.x. Eur J Neurol. 2000. PMID: 11136353

10

Circadian heart rate variability in Parkinson's disease.

Pursiainen V, Haapaniemi TH, Korpelainen JT, Huikuri HV, Sotaniemi KA, Myllylä VV. Pursiainen V, et al. Among authors: myllyla vv. J Neurol. 2002 Nov;249(11):1535-40. doi: 10.1007/s00415-002-0884-0. J Neurol. 2002. PMID: 12420094

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters